trending Market Intelligence /marketintelligence/en/news-insights/trending/ACaxHOZ3yWE-RBa5fK-kVw2 content esgSubNav
In This List

Novo Nordisk wins FDA panel endorsement for diabetes drug

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Novo Nordisk wins FDA panel endorsement for diabetes drug

A U.S. Food and Drug Administration advisory panel recommended approving the Novo Nordisk A/S diabetes drug semaglutide.

The Endocrinologic and Metabolic Drugs Advisory Committee voted 16-0, with one abstention, in favor of the approval.

Data showed that semaglutide was linked with an initial worsening of diabetic retinopathy but the panelists noted that this risk was offset by the benefit of reducing blood sugar overall, Reuters reported Oct. 18.

Diabetic retinopathy is a diabetes complication that affects the eyes.

The agency is not required to follow the recommendations of its advisers but often does.